194 completed, 32 unknown, 19 terminated, 14 recruiting. 278 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 278 | Completed 194, Unknown 32, Terminated 19, Recruiting 14, Withdrawn 8, Not yet recruiting 6, Active not recruiting 5 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution - Glaucoma, Glaucoma, Open-Angle | Phase 4 | Not yet recruiting | Tulane University | 60 | 2027-11-01 | 2026-10-13 |
| Baerveldt Versus Paul Study Baerveldt Glaucoma Implant, Paul Glaucoma Implant - Glaucoma | Phase 4 | Not yet recruiting | University of Sydney | 150 | 2026-10-12 | 2026-08-03 |
| Switching From Preserved Glaucoma Therapy to Preservative-Free ZOLYMBUS preservative free ZOLYMBUS™ 0.01%. - Eye Drops Self-instillation, Glaucoma | Phase 4 | Not yet recruiting | Southern College of Optometry | 40 | 2026-10-05 | 2026-09-28 |
| Iopidine to Decrease Intraocular Pressure Rise After Injections Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Retina Consultants of Delmarva | 120 | 2026-10-01 | 2026-10-23 |
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-10-28 |
| Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH Preservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension | Phase 4 | Active not recruiting | Tecnoquimicas | 140 | 2026-06-10 | 2026-07-08 |
| Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT) - Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Indiana University | 50 | 2026-06-05 | 2026-06-11 |
| Rocklatan vs Latanoprost Post-DSLT Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Glaucoma | Phase 4 | Recruiting | Eye Centers of Southeast Texas | 36 | 2026-05-14 | 2026-05-22 |
| Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use Durysta, Bimatoprost Intracameral Implant 10 µg - Glaucoma, Open-Angle Glaucoma | Phase 4 | Recruiting | University of Miami | 20 | 2026-02-09 | 2026-03-05 |
| Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg - Open Angle Glaucoma, Pigmentary Glaucoma | Phase 4 | Recruiting | Jonathon Myers | 20 | 2026-01-05 | 2025-11-14 |
| Rocklatan Retinal Perfusion OCT Study Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months., Two optical coherence tomography (OCT) devices will be used to assess blood flow changes. - Glaucoma | Phase 4 | Not yet recruiting | Oregon Health and Science University | 30 | 2026-01-01 | 2025-12-24 |
| 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Mayo Clinic | 30 | 2025-11-21 | 2026-05-01 |
| Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma Brimonidine Tartrate Ophthalmic 0.025% - Glaucoma | Phase 4 | Recruiting | Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | 35 | 2025-11-01 | 2025-11-18 |
| Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane - Primary Open Angle Glaucoma | Phase 4 | Not yet recruiting | Center for Sight Las Vegas | 68 | 2025-07-15 | 2025-07-03 |
| Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT Netarsudil ophthalmic solution 0.02%, Artificial tears - Primary Open Angle Glaucoma or Ocular Hypertension | Phase 4 | Active not recruiting | East Coast Institute for Research | 70 | 2025-06-27 | 2026-06-10 |
| Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution - Open Angle Glaucoma | Phase 4 | Recruiting | Prairie Eye Center | 70 | 2025-05-14 | 2025-05-15 |
| Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery - Glaucoma, Open-angle, Ocular Hypertension (OHT) | Phase 4 | Recruiting | Glaukos Corporation | 132 | 2025-01-13 | 2026-01-21 |
| A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma Oral semaglutide, Placebo - Primary Open Angle Glaucoma (POAG), Open-Angle Glaucoma | Phase 4 | Recruiting | Glostrup University Hospital, Copenhagen | 126 | 2025-01-01 | 2025-01-24 |
| Comparison of Visual Field Assessments Between Three Perimeters Visual field assessment - Glaucoma | Phase 4 | Completed | Gainesville Eye Associates | 54 | 2024-11-18 | 2026-04-30 |
| Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT Ketorolac 0.5% Eye Drops, Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Unknown | St. Joseph's Healthcare Hamilton | 126 | 2024-09-01 | 2024-07-12 |
Showing 20 of 278. Sign in to see all of them.
Glaucoma, Open-Angle (135) · Ocular Hypertension (122) · Eye Diseases (9) · Low Tension Glaucoma (8) · Cataract (6) · Dry Eye Syndromes (6) · Hypertension (4) · Glaucoma, Angle-Closure (3) · Patient Compliance (3) · Diabetic Retinopathy (2) · Exfoliation Syndrome (2) · Glaucoma, Neovascular (2) · Hyperemia (2) · Retinal Vein Occlusion (2)
Eye Diseases (269) · Ocular Hypertension (156) · Cardiovascular Diseases (9) · Optic Nerve Diseases (9) · Vascular Diseases (9) · Lacrimal Apparatus Diseases (6) · Lens Diseases (6) · Endocrine System Diseases (4) · Retinal Diseases (4) · Uveal Diseases (4) · Behavior (3) · Health Behavior (3) · Nervous System Diseases (3) · Patient Acceptance of Health Care (3)
Latanoprost (63) · Timolol (55) · Travoprost (53) · Bimatoprost (37) · Ophthalmic Solutions (34) · Brimonidine Tartrate (31) · brinzolamide (29) · dorzolamide (23) · dorzolamide-timolol combination (22) · Duotrav (13) · Azarga (12) · tafluprost (12) · Brimonidine Tartrate, Timolol Maleate Drug Combination (10) · Trabeculectomy (10) · Lubricant Eye Drops (9)
Alcon Research (51) · Allergan (26) · Glaukos Corporation (14) · Aristotle University Of Thessaloniki (13) · Innovative Medical (5) · Pharmaceutical Research Network (5) · Federal University of São Paulo (4) · Indiana University (4) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (4) · Wills Eye (4) · CHA University (3) · Medical University of Vienna (3) · Nova Scotia Health Authority (3) · Sensimed AG (3) · Aerie Pharmaceuticals (2)
United States (89) · Canada (26) · Italy (18) · Germany (14) · Greece (13) · Spain (12) · Austria (10) · South Korea (10) · Switzerland (10) · Armenia (9) · United Kingdom (8) · Brazil (7) · France (7) · China (6) · India (6)
William C. Stewart, MD (6) · Anastasios G Konstas, MD, PhD (5) · Robert Noecker, MD (5) · Abayomi Ogundele, PharmD (4) · Louis B Cantor, MD (3) · Severine Durier, Pharm.D (3) · Anastasios GP Konstas, MD, PhD (2) · Anna Grau (2) · Anthony D Realini, MD (2) · Danyel Carr, MS (2) · Elizabeth D. Sharpe, MD (2)
PMID 36912740, PMID 19476406, PMID 10937547, PMID 11589866, PMID 12614754, PMID 14509472, PMID 14736774, PMID 14996520, PMID 16249960, PMID 16303952, PMID 17102003, PMID 17122118, PMID 17191187, PMID 17415690, PMID 17686450, PMID 18173426, PMID 18402717, PMID 18826749, PMID 19157559, PMID 19668762, PMID 19825835, PMID 19882583, PMID 20181282, PMID 20505839, PMID 20553122, PMID 20668720, PMID 21048504, PMID 21330656, PMID 21773673, PMID 21960068, PMID 22205835, PMID 22458918, PMID 22918671, PMID 23475405, PMID 23681371, PMID 24006861, PMID 24452726, PMID 24855336, PMID 25432143, PMID 25519810, PMID 25982212, PMID 26563363, PMID 27162226, PMID 27293875, PMID 27913991, PMID 28034308, PMID 28239491, PMID 28454526, PMID 28617732, PMID 29226268
R01EY022124 (2), 2009 (1), 2015 (1), 2016 (1), 2019 (1)